By indication / Dosimetry and biodistribution studies
Dosimetry and biodistribution studies
32 imaging agents and 41 therapeutic agents reported for this indication. Stage reflects how far each has been taken, not what is available in any given country.
Imaging
| Agent | Isotope | Stage | Runs |
|---|---|---|---|
| [68Ga]Ga-PSMA-617 | Ga-68 | Clinical research | 9 |
| [18F]rhPSMA-7 paired with [177Lu]Lu-rhPSMA-7 | F-18 | Clinical research | 4 |
| [18F]AmBF3-TATE | F-18 | Preclinical | 3 |
| [18F]PBR111 | F-18 | — | 3 |
| [111In]In-RM2 paired with [68Ga]Ga-RM2 | In-111 | Research | 2 |
| [18F]FEDAA1106 | F-18 | Clinical research | 2 |
| [18F]PBR102 | F-18 | Preclinical | 2 |
| 10-[11C]methoxy-20(S)-camptothecin | C-11 | Preclinical | 1 |
| [11C]PD153035 | C-11 | Clinical research | 1 |
| [18F]ApaScan | F-18 | Preclinical | 1 |
| [18F]BTK-1 | F-18 | Preclinical | 1 |
| [18F]FB-A20FMDV2 | F-18 | Preclinical | 1 |
| [18F]FBEM-Cys-H4 | F-18 | Preclinical | 1 |
| [18F]MEL050 | F-18 | Clinical research | 1 |
| [68Ga]Ga-BOT5035 | Ga-68 | Clinical research | 1 |
| [111In]DOTA-MSC3 paired with [225Ac]Ac-DOTA-MSC3 | In-111 | Preclinical | 1 |
| [111In]BCY18469 | In-111 | Preclinical | 1 |
| [68Ga]NOTA-MI-exendin-4 | Ga-68 | Preclinical | 1 |
| [68Ga]HTK03149 paired with [177Lu]Lu-HTK03149 | Ga-68 | Reported once | 1 |
| [89Zr]hu5A10 | Zr-89 | Preclinical | 1 |
| [99mTc]Tc(CO)3-ADAPT6 | Tc-99m | Preclinical | 1 |
| [111In]In-PSMA-617 paired with [177Lu]Lu-PSMA-617 | In-111 | Research | |
| [11C]KIn83 | C-11 | — | |
| [11C]Me-NB1 | C-11 | Clinical research | |
| [18F]AF78 | F-18 | Clinical research | |
| [18F]fiau | F-18 | Clinical research | |
| [18F]fluoro-3-(2(S)-azetidinylmethoxy)pyridine | F-18 | — | |
| [18F]fluorophenylalanine | F-18 | Clinical research | |
| [18F]L-Glutamic | F-18 | Clinical research | |
| [68Ga]Ga-oxine | Ga-68 | Clinical research | |
| [68Ga]Ga-P16-093 | Ga-68 | Clinical research | |
| [89Zr]vMET1-Fc paired with [177Lu]Lu-vMET1-Fc | Zr-89 | Preclinical |
Therapy
Other entries
| Agent | Isotope | Stage | Runs |
|---|---|---|---|
| [111In]In-minigastrin | In-111 | — | 2 |
| [111In]In-exendin | In-111 | — | 2 |
| [125I]CPCR4.3 | I-125 | Preclinical | 1 |
| [64Cu]CuCl2 | Cu-64 | Clinical research | 1 |
| [90Y]Y-DOTA-AR | Y-90 | Preclinical | 1 |
| [111In-DTPA]MG0 | In-111 | — | 1 |
| [166Ho]Ho-DTPA | Ho-166 | Preclinical | |
| [131I]I-omburtamab | I-131 | Clinical research | |
| [225Ac]Ac-HuM195 | Ac-225 | Preclinical | |
| [188Re]Re-Liposome | Preclinical | ||
| [11C]3-MeO-4-AP | C-11 | Preclinical | |
| [212Pb]Pb-VMT-alpha-NET | Pb-212 | Clinical research | |
| [111In]In-labeled NZ-16 | In-111 | Preclinical | |
| [111In]In-DOTA-IgG | Preclinical | ||
| [188Re]Re-IBA | Re-188 | — | |
| [99mTc]Tc-BMEDA liposomes | Tc-99m | — | |
| [188Re]Re-C1P5 | Re-188 | Preclinical | |
| [67Cu]Cu-TCPP | Cu-67 | — |
Have a question?Reagents, modules, introductions to manufacturers or to specialists in your region - tell us what you need.
Get in touch